Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Respiratory Illness season is right around the corner and experts are urging parents to take action to protect their newborns ...

Health experts are warning of a potential 'tripledemic' this winter - here's how to spot the early symptoms of flu, RSV and ...

Clesrovimab is an extended half-life RSV neutralizing antibody in development for all infants in their first RSV season and ...

The NHS has listed the symptoms of covid, RSV and flu to help you tell the difference between each one, as cases forecast to ...

EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...

Health experts highlight how this highly contagious disease affects vulnerable populations and share insights on prevention ...

Despite being back in the season of sniffles and sick days, Washington state will be extra equipped to battle the spread of respiratory viruses this year.

MOBILE, Ala. ( WALA) - At USA Health Children’s & Women’s Hospital, doctors are seeing a rise in pediatric RSV cases. Dr.

Merck & Co., Inc. (MRK) announced the positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the ...

A mother’s worst nightmare is watching her child fall gravely ill, feeling helpless as the condition becomes worse. When ...

(Corrects headline, paragraph 1 and 2 in Oct. 17 story to show the drug reduced medically attended lower respiratory ...